ROCKLAND IMMUNOCHEMICALS, INC.

Basic Information

PO BOX 5199, 321 JONES BLVD
LIMERICK, PA 19468-5199
POTTSTOWN, PA, 19464-3468

Company Profile

n/a

Additional Details

Field Value
DUNS: 058999129
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Synthetic antibodies for monitoring modified RNAs

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): Post-transcriptional RNA modification plays an important role in biological processes. For example, adenosines to nosiness or A-to-I editing are most abundant in t ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Antibody-based Point-of-Care Device for the Diagnosis of Sickle Cell Disease

    Amount: $449,072.00

    DESCRIPTION (provided by applicant):. Hemoglobinopathies are the most common monogenic diseases with approximately 7% of the world's population being carriers. Sickle cell disease (SCD) and thala ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. TOPIC 324 PHASE I 9 MONTH FUNDING; NOVEL IMAGING AGENTS T EXPAND TE CLINICAL TOOL

    Amount: $249,975.00

    Medical imaging and targeted therapy are the central components in the clinical management of cancer patients. Rockland Immunochemicals, Inc. is teaming up with Abzyme Therapeutics LLC to develop nove ...

    SBIR Phase I 2013 Department of Health and Human Services
  4. MULTIPLEXED ASSAYS FOR AKT/M TOR PATHWAY- PHASE I SBIR TOPIC

    Amount: $149,937.00

    PTEN/Akt/mTORC 1and2 signal pathway is a critical regulator of cell survival, cell growth and proliferation, angiogenesis, cellular metabolism, cell migration and invasion and glucose uptake. A number ...

    SBIR Phase I 2010 Department of Health and Human Services
  5. Not Available

    Amount: $299,954.00

    Antibody therapy offers treatment for a wide range of diseases and can extend the life of cancer patients, but the treatment cost is extremely expensive. as patent protection of some current antibodie ...

    SBIR Phase I 2010 Department of Health and Human Services
  6. Novel Point-of-Care Multiplex Lyme Disease Test

    Amount: $315,172.00

    DESCRIPTION (provided by applicant): Lyme disease (LD) is caused by spirochetal bacteria from the genus Borrelia. Borrelia burgdorferi is the predominant cause of Lyme disease in the United States, wh ...

    SBIR Phase I 2009 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government